2018慢性胰腺炎消化不良患者应用复方阿嗪米特与盐酸伊托必利联合治疗

1373342

　　[摘要] 目的 探究慢性胰腺炎合并消化不良患者在治疗过程中应用复方阿嗪米特联合盐酸伊托必利干预的价值。方法 方便选取该院消化内科慢性胰腺炎消化不良患者100例，选取时间为2016年3月―2016年8月，根据患者治疗方案的不同进行分组，其中对照组仅接受盐酸伊托必利治疗，实验组则接受盐酸伊托必利与复方阿嗪米特联合治疗，对比两组慢性胰腺炎消化不良患者治疗后症状评分、不良反应等的差异性。 结果 实验组症状评分（腹痛、腹胀、食欲不振、嗳气、早饱）分别为（0.71±0.66）分、（0.75±0.58）分、（0.80±0.11）分、（1.02±0.29）分、（0.41±0.05）分均明显低于对照组（P0.05）。结论 采取复方阿嗪米特与盐酸伊托必利联合治疗慢性胰腺炎消化不良的效果显著，且具有较高的安全性。
http://
　　[关键词] 胰腺炎；阿嗪米特；伊托必利；消化不良
　　[中图分类号] R4 [文献标识码] A [文章编号] 1674-0742（2018）01（b）-0118-03
　　[Abstract] Objective To study the value of azintamide and itopride hydrochloride in patients with chronic Pancreatitis with dyspepsia. Methods 100 cases of patients with chronic pancreatitis with dyspepsia in our hospital from March 30， 2016 to August 2016 were commodiously selected and divided into two groups according to different treatment plans， the control group were treated with simple itopride hydrochloride， while the experimental group were treated with azintamide and itopride hydrochloride， and the symptom score and adverse reactions of patients were compared between the two groups. Results The symptom scores （abdominal pain， abdominal distension， loss of appetite， belching， early satiety） in the experimental groups were respectively （0.71±0.66）points， （0.75±0.58）points， （0.80±0.11）points， （1.02±0.29）points， （0.41±0.05）points， which were obviously lower than those in the control group， P0.05）. Conclusion The effect of azintamide and itopride hydrochloride in patients with chronic Pancreatitis with dyspepsia is obvious with high safety.
　　[Key words] Pancreatitis； Azintamide； Itopride； Dyspepsy
　　以往为慢性胰腺炎消化不良患者实施治疗是以单独盐酸伊托必利为主，但是其疗效并不理想，相关研究表明，在为患者实施盐酸伊托必利治疗的过程中，与复方阿嗪米特联合使用，则可以将治疗的疗效提高[1]。该研究对2016年3月―2016年8月收治的慢性胰腺炎消化不良患者50例实施复方阿嗪米特联合盐酸伊托必利干预获得了较为显著的效果，以50例行盐酸伊托必利治疗的患者为对照，现报道如下。
　　1 资料与方法